Teikoku to decide future of Aricept patch alone as it pulls US NDA
This article was originally published in Scrip
Teikoku Seiyaku has decided to withdraw a US new drug application for a transdermal patch formulation of Eisai's Alzheimer's disease drug Aricept (donepezil), following the rejection of the product by the FDA around a year ago.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.